Abstract
The incidence of prematurity in Germany is about 10% and premature infants with haemophilia A (OMIM 306700) are in fact very rare. We report two new cases, one born in the 28th gestational week, weighing 1200 g with a factor VIII (FVIII) level of 0.03 IU/ml treated with bolus injections of plasma derived FVIII concentrate (pdFVIII), and one born at week 30, weighing only 710 g with a factor level of <0.01 IU/ml and treated with recombinant FVIII concentrate (rFVIII). Recovery of FVIII was 96% in case 1 and 120% in case 2, FVIII half-life was 6 h and 8 h, respectively. During FVIII substitution, neither bleeding, thrombosis nor inhibitor development were noted in both infants. Conclusion:Immediate and frequent factor VIII substitution appears to be safe and effective for prophylaxis and treatment in premature haemophilic neonates.
Similar content being viewed by others
Abbreviations
- FVIII :
-
factor VIII
- IVH :
-
intraventricular haemorrhage
- pdFVIII :
-
plasma derived factor VIII concentrate
- rFVIII :
-
recombinant factor VIII concentrate
- vWF :
-
von Willebrand factor
References
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P (1988) Development of the human coagulation system in the healthy premature infant. Blood 72: 1651–1657
Chalmers EA (2004) Haemophilia and the newborn. Blood Rev 18: 85–92
Gale RF, Hird MF, Colvin BT (1998) Management of a premature infant with moderate haemophilia A using recombinant factor VIII. Haemophilia 4: 850–853
Giangrande PLF (2003) Pregnancy in women with inherited bleeding disorders. World Federation of Hemophilia, Montreal
Klinge J, Auberger K, Auerswald G, Brackmann HH, Mauz-Korholz C, Kreuz W (1999) Prevalence and outcome of intracranial haemorrhage in haemophiliacs—a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 158[Suppl 3]: S162–S165
Kulkarni R, Lusher J (2001) Perinatal management of newborns with haemophilia. Br J Haematol 112: 264–274
Lusher J (2004) Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2: 863–865
Scharrer I, Bray GL, Neutzling O (1999) Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5: 145–154
Acknowledgements
The authors wish to thank all involved clinicians, especially Dr. Garhammer and her team of the Neonatal Intensive Care Unit, Children’s Hospital Dritter Orden, Munich, Germany, and the neonatologists of the Allgemeines Krankenhaus Celle, Germany and the Children’s Hospital, Medical School Hannover, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bidlingmaier, C., Bergmann, F. & Kurnik, K. Haemophilia A in two premature infants. Eur J Pediatr 164, 70–72 (2005). https://doi.org/10.1007/s00431-004-1542-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-004-1542-6